EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review

Ashish Sharma, Nilesh Kumar

EyeQuest · 2024

DOI: 10.4103/equest.equest_25_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EyeQuest, 2024. Verfasst von Ashish Sharma und 1 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age-related macular degeneration (AMD) remains a leading cause of irreversible vision loss worldwide, with neovascular AMD accounting for the majority of severe vision loss cases. Current treatments, primarily anti-vascular endothelial growth factor (anti-VEGF) therapies, have revolutionized AMD management but are limited by the need for frequent intravitreal injections. Gene therapy has emerged as a promising approach to address these limitations, offering the potential for long-term therapeutic effects from a single administration. This review examines the latest advancements in gene therapy for neovascular AMD, focusing on current approaches, delivery systems, and clinical progress. Anti-angiogenic strategies, including VEGF trap and anti-VEGF antibody gene therapies, are at the forefront of clinical development. Promising candidates like RGX-314 and ADVM-022 have demonstrated sustained VEGF suppression and reduced treatment burden in early-phase trials. Neuroprotective, anti-inflammatory, and complement modulation approaches are also being explored to address the multifaceted nature of AMD pathogenesis. Advancements in vector engineering, particularly with adeno-associated virus variants, have improved gene delivery efficiency and specificity. Novel administration routes, such as suprachoroidal delivery, are being investigated to optimize safety and efficacy. While early clinical data show encouraging safety profiles and potential for long-term efficacy, challenges remain, including immune responses to vectors and transgenes, and the need for precise dosing and administration techniques. As gene therapy for neovascular AMD progresses, key areas for future research include optimizing vector design for enhanced retinal penetration, developing combinatorial approaches targeting multiple disease pathways, and exploring personalized treatment strategies based on genetic risk profiles. The potential of gene therapy to provide durable therapeutic effects with a single administration holds promise for transforming AMD management, potentially improving patient outcomes and quality of life while reducing healthcare burden.

Zitieren

APA

Sharma, A., & Kumar, N. (2024). Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review. EyeQuest. https://doi.org/10.4103/equest.equest_25_24

Vancouver

Sharma A, Kumar N. Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review. EyeQuest. 2024. doi:10.4103/equest.equest_25_24

BibTeX
@article{Sharma2024,
  author = {Sharma, Ashish and Kumar, Nilesh},
  title = {Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review},
  journal = {EyeQuest},
  year = {2024},
  doi = {10.4103/equest.equest_25_24}
}
Kostenlos starten →